Elevance Health (ELV) Earnings Date & Reports
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025... Show more
ELV is expected to report earnings to fall 50.79% to $6.19 per share on July 22
Elevance Health (ELV) Q1 2026 Earnings Recap: Beats Expectations and Raises Full-Year Outlook
Key Takeaways
- Elevance Health reported Q1 2026 operating revenue of $49.5 billion, up 1.5% year-over-year and beating consensus estimates around $48.3 billion.
- Adjusted diluted earnings per share (EPS, a measure of profitability) reached $12.58, surpassing analyst expectations of approximately $10.74 to $10.84 by more than 16%.
- GAAP diluted EPS stood at $8.00, impacted by a $935 million accrual related to a Centers for Medicare & Medicaid Services (CMS) matter.
- Medical benefits ratio (MBR, the portion of premiums spent on medical claims) was 86.8%, up 40 basis points from the prior year.
- The company raised its full-year 2026 adjusted diluted EPS guidance to at least $26.75 and reaffirmed operating cash flow outlook of at least $5.5 billion.
- Medical membership totaled approximately 45.4 million as of March 31, 2026, reflecting growth in commercial segments offset by declines in Medicare Advantage and risk-based employer group.
Earnings Context and Why It Matters
As one of the largest U.S. health insurers by membership, Elevance Health's quarterly results offer critical insights into the health benefits sector amid ongoing pressures from medical cost trends, regulatory changes, and membership shifts. Q1 2026 earnings are particularly noteworthy following a strong Q4 2025 performance and amid industry scrutiny over Medicare Advantage risk adjustments. Investors watch these reports closely for signals on profitability, cost management, and growth in diversified segments like Carelon services, which impact stock valuation and sector peers.
Elevance Health delivered solid Q1 2026 results for the three months ended March 31, 2026. Operating revenue rose to $49.5 billion, a 1.5% increase from $48.8 billion in Q1 2025, driven by higher premium yields in Health Benefits and 7.9% growth in Carelon revenue to $18.0 billion. This topped consensus revenue forecasts of about $48.3 billion.
Adjusted diluted EPS hit $12.58, up from $11.97 in the prior-year quarter and well above expectations of $10.74, aided by favorable claims experience and approximately $1 per share in non-recurring investment income. GAAP diluted EPS was $8.00, reflecting the $935 million CMS accrual and a $129 million optimization charge, which elevated the operating expense ratio to 12.8% (adjusted: 10.5%).
Health Benefits operating gain was $2.2 billion (down 2.7% YoY), while Carelon's was $1.1 billion (down 3.8%). Operating cash flow strengthened to $4.3 billion, up significantly YoY. Management highlighted business strength and medical cost improvements exceeding expectations.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
ELV shares rose approximately 2-3% in pre-market and intraday trading on April 22, 2026, following the earnings release, reflecting investor approval of the EPS beat and raised guidance despite the CMS accrual and slightly elevated MBR. Sentiment turned positive on the company's outlook confidence, though some caution lingered over Medicare headwinds and regulatory risks.
Forward Outlook and Key Factors to Monitor
Elevance Health's raised full-year 2026 adjusted EPS guidance to at least $26.75 signals optimism from medical cost reductions and operational efficiencies, building on Q1 momentum. Investors should track progress against this outlook, particularly the impact of the CMS risk-adjustment matter and potential payments, which could boost cash flows.
Key areas include membership dynamics, with growth in commercial fee-for-service offsetting Medicare Advantage and Medicaid declines. Monitor the MBR trajectory amid elevated trends in Medicaid and any Medicare improvements. Carelon segment expansion and AI-driven optimizations in claims processing are highlighted as growth drivers.
Broader factors like regulatory changes in Medicare Advantage, employer group demand, and pharmacy benefit management trends via CarelonRx will shape performance. Upcoming Q2 results and annual shareholder meeting on May 13, 2026, may provide further clarity on these elements.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a provider of life, hospital and medical insurance plans
Industry ManagedHealthCare